Entera Bio Ltd (ENTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.96 (-2.31%), Market cap $0.07B, 52-week low–high $1.00 ~ $3.14.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial
Financial statements, price targets, institutional (13F) holdings and related news for Entera Bio Ltd are updated in real time on BlackAll Trade.
Entera Bio Ltd trades at $2.96 (-2.31%). Real-time quotes and charts are available on BlackAll Trade.
Entera Bio Ltd has a market cap of about $0.07B.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which c